IFP Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

IFP Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-105	Closed	-$24	–	3598
2023 Q2	$24	Buy	+105	New	+$346	﹤0.01%	3416
2019 Q1	–	Sell	-2	Closed	–	–	3568
2018 Q4	$0	Hold	2	–	–	﹤0.01%	3922
2018 Q3	$0	Hold	2	–	–	﹤0.01%	4052
2018 Q2	$0	Hold	2	–	–	﹤0.01%	4097
2018 Q1	$1K	Hold	2	–	–	﹤0.01%	3687
2017 Q4	$1K	Hold	2	–	–	﹤0.01%	3738
2017 Q3	$1K	Hold	2	–	–	﹤0.01%	3977
2017 Q2	$1K	Hold	2	–	–	﹤0.01%	3972
2017 Q1	$1K	Hold	2	–	–	﹤0.01%	3879
2016 Q4	$1K	Hold	2	–	–	﹤0.01%	3868
2016 Q3	$2K	Hold	2	–	–	﹤0.01%	3633
2016 Q2	$2K	Buy	+2	New	+$2.51K	﹤0.01%	3514
2016 Q1	–	Sell	-2	Closed	-$5K	–	3554
2015 Q4	$5K	Buy	+2	New	+$3.07K	﹤0.01%	2994

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

IFP Advisors's NBSE Position: Q3 2023 in Review

IFP Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2023, closing a stake of 105 shares — an estimated $24 sold.

IFP Advisors first reported a position in NBSE in Q4 2015 and held it in 13 quarters. The position peaked at $5K in Q4 2015. 21 funds tracked by Wall St. Rank hold NBSE as of Q3 2023.

IFP Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
IFP Advisors sold 105 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $24.
IFP Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2015 and held it in 13 quarters.
IFP Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $5K in Q4 2015.
21 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2023.

Based on IFP Advisors's 13F filing for Q3 2023, filed 12 Oct 2023.